On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use Listing (EUL) for NVX-CoV2373, Novavax’ recombinant protein nanoparticle COVID-19 vaccine with Matrix-Mﾙ adjuvant, for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

The EUL follows the receipt of conditional marketing authorization from the European Commission and prequalifies Nuvaxovid as meeting WHO standards for quality, safety and efficacy. EUL is a prerequisite for exports to numerous countries, including those participating in the COVAX Facility, which was established to enable equitable vaccine allocation and distribution.